Bristol-Myers’ buyout of Celgene approved by deeply divided FTC

Federal Trade Commission member Noah Phillips’ exasperation is palpable.

Responding to the dissents of his two Democratic colleagues opposing the settlement to allow Bristol-Myers Squibb’s $74 billion acquisition of Celgene, Phillips...

Subscription required to view this article.

This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content

If you do not currently subscribe to FTCWatch please contact us for subscription information:

FTCWatch is delivered in the following formats: via email alert and online at